Long Cast Advisers, a distinguished independent investment firm, recently shared its Q2 2026 investor letter. This report disclosed robust financial performance for the quarter, with a 20% improvement in earnings, pushing year-to-date returns to an impressive +19%. While these returns did not surpass the Russell 2000 or the iShares US MicroCap ETF, they significantly outpaced the iShares SmallCap EAFE (ex-N. Am) ETF. Since its establishment in 2015, the firm has achieved cumulative returns of 343%, representing a 15% compound annual growth rate (CAGR), a testament to its disciplined approach of focused, long-term investments in smaller market capitalization companies. In the current economic climate, the firm emphasizes a cautious stance, prioritizing patience and resilience while avoiding excessive leverage and market volatility.

A key focus of Long Cast Advisers' Q2 2026 letter was Pro-Dex, Inc., a global medical device company known for designing, developing, manufacturing, and distributing powered surgical instruments to original equipment manufacturers (OEMs). On August 7, 2026, Pro-Dex's shares closed at $65.56, demonstrating a one-month gain of 7.88% and a remarkable 72.87% increase over the preceding 52 weeks, bringing its market capitalization to $209.32 million. The investment firm's analysis underscored the potential for Pro-Dex, Inc. to experience a significant uplift in operational cash flow through the successful commercialization of Zimmer's mBos robot. Long Cast Advisers quantified the projected benefits, basing their estimates on public filings and an informed assumption of four effectors per system sale. The firm noted that Zimmer's acquisition of Monogram included contingent valuation rights (CVRs) that would provide $3.41 per share annually from 2028 to 2030, contingent on mBos gross revenues exceeding specific thresholds. Based on these projections, the required number of systems to achieve these revenues aligns with a capital sale of approximately $1 million per machine, comparable to Stryker's Mako platform. The forecast of 609 units needed to trigger the final CVR appears attainable, especially considering Stryker's sale of 860 units within its first three years. Long Cast Advisers believes that even if the timing or estimates are not entirely precise, the overall direction remains positive, with Zimmer allocating substantial resources to the launch, positioning Pro-Dex for an extraordinary transformation in its operating cash flow, thereby justifying a considerably higher corporate valuation. This strategic positioning solidifies Pro-Dex's status as a top holding for the firm.

The strategic partnership between Pro-Dex and Zimmer, particularly with the anticipated success of the mBos robot, signifies a forward-looking approach in the medical device sector. This collaboration highlights the importance of innovation and strategic alliances in driving corporate value and fostering long-term growth. The emphasis on patient, concentrated investments, as practiced by Long Cast Advisers, demonstrates a belief in the inherent value of well-positioned companies, encouraging a steadfast commitment to growth and technological advancement in a dynamic market environment.